权威！WHO将发布新版“减肥指南”，拟首次推荐司美格鲁肽等GLP-1减肥药

Core Viewpoint - The World Health Organization (WHO) is set to release new guidelines for the treatment of adult obesity using GLP-1 receptor agonists (GLP-1 RAs), marking a significant shift in its approach to addressing the global obesity crisis [1][3]. Group 1: Guidelines and Recommendations - The guidelines aim to clarify the clinical indications, applications, and management pathways for GLP-1 RAs in treating adult obesity, potentially being the first formal recommendation of weight-loss medications by WHO [1][3]. - An independent development group (GDG) composed of experts from various fields is leading the guideline formulation to ensure high standards of scientific validity and applicability [1]. Group 2: Obesity as a Global Health Crisis - WHO has defined obesity as a global health crisis, with over 1 billion people affected worldwide, and approximately 70% of these individuals living in low- and middle-income countries (LMIC) [5]. - The rising prevalence of obesity is linked to various chronic diseases, with about 90% of obese patients having at least one comorbid condition [1][5]. Group 3: GLP-1 Drugs and Market Potential - GLP-1 drugs are gaining recognition for their dual ability to lower blood sugar and control weight, with a projected increase in potential user coverage from 4% in 2023 to 12% by 2025 [3]. - WHO plans to include GLP-1 receptor agonists in the Essential Medicines List (EML), emphasizing their safety, efficacy, and affordability, particularly for low- and middle-income countries [3][4]. Group 4: Accessibility and Cost Concerns - WHO highlights the need to improve the accessibility of weight-loss medications in LMICs, where most obese patients reside [4]. - The initial high cost of GLP-1 drugs, exceeding $1,000 per month, poses a significant barrier for many patients, despite some price reductions in certain markets [5][7].